Voluntary License Agreement For Remdesivir – Intellectual Property | Instant News


To print this article, all you need is to register or login at Mondaq.com.

Gliead works quickly
fight with this broken COVID-19 novel. Remdesivir is a
potential drug for the treatment of COVID-19. Remdesivir has
officially not approved as a COVID-19 treatment. USA uses
appropriate authority for drug investigations. That
There are several clinical trials conducted to check safety and
treatment efficiency of Remdesivir Covid-19.

Gilead works with regulation
an agent to provide remdesivir to patients. Until now Gliead is
provide emergency access to remdesivir for several hundred
patients in the United States, Europe and Japan

According to reports from
the STAT medical news website for this drug shows Remdesivir positive
Respond to COVID-19 patients. The University of Chicago
The medical center also participates in antiviral studies
medication and say that there is a rapid recovery of symptoms
Covid-19 because of this drug. Remdesivir’s previous medication
tested on Ebola patients now being tested for COVID-19
patient. Not only does Gilead conduct its own clinical trials
making drugs available for studies run by other sponsors.

Gilead has now signed
exclusive voluntary license agreement. Where it was given
licenses for drug makers from India and Pakistan to expand supply
from experimental drugs used in COVID-19 patients.

“Non-Exclusive License
is a license that can be granted to more than one entity. For
for example, a patent holder can grant a non-exclusive license to
several generic drug manufacturers.

Voluntary license is a
Voluntary agreement reached between patent holders (licensor)
and licensees. The terms and conditions of the license are agreed
between the patent holder and the licensee, and can determine where
state of the drug can be sold and what the royalty is. That
MPP is a mechanism that manages voluntary licensing among many
licensors and licensees “.

Companies that will produce Remdesivir drugs
is:

Indian company,
Jubilant Life Sciences Ltd, headquartered in Noida, Mumbai
Cipla Ltd, Hetero Labs Ltd based in Hyderabad and two others
is a US-based company Mylan NV and Ferozsons based in Pakistan
Laboratories Ltd. These companies are allowed to develop and sell
medicine in 127 countries.

In 127 countries, countries
most low-income, low-middle-income countries &
several middle and upper income countries.

Furthermore, USFDA has granted Emergency Use Authorization (EUA)
for the drug Remdesivir to treat COVID-19 patients. Japan, too
approved this drug to treat COVID-19 patients.

Gilead has transfer technology
to five generic drug companies for manufacturing, so
this drug is available as soon as possible. Gilead also said
that they will set their own prices for generic products
they produce.

Also stated that drugs
will be royalty free until or unless WHO announces the end of the public
health emergencies regarding Covid-19 or when there are other vaccines
versus remdesivir to treat or prevent COVID-19, depending on which one
previous.

That the agreement permits distribution as follows
country:

Afghanistan, Algeria, Angola,
Anguilla, Antigua & Barbuda, Armenia, Aruba, Azerbaijan,
Bahamas, Bangladesh, Barbados, Belarus, Belize, Benin, Bermuda,
Bhutan, Botswana, British Virgin Islands, Burkina Faso, Burundi,
Cambodia, Cameroon, Cape Verde, Cayman Island, Central Af R., Chad,
Comoros, Republic of the Congo, Cook Islands, Costa Rica, Ivory Coast,
Cuba, Curacao, Djibouti, Dominica, Dominican Republic, Egypt, El
Salvador, Equatorial Guinea, Eritrea, Eswatini (Swaziland),
Ethiopia, Fiji, Gabon, Gambia, Georgia, Ghana, Grenada,
Guatemala, Guinea, Guinea Bus, Guyana, Haiti, Honduras, India,
Indonesia, Jamaica, Kazakhstan, Kenya, Kiribati, Korea, Dem.
People’s Republic (North Korea), Kyrgyzstan, Lao DR (Laos),
Lesotho, Liberia, Libya, Madagascar, Malawi, Maldives, Mali,
Marshall Islands, Mauritania, Mauritius, Micronesia, The Fed.
Sts., Moldova, Mongolia, Montserrat, Morocco, Mozambique, Myanmar,
Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, Pakistan, Palau,
Panama, Papua New Guinea, Philippines, Rwanda, Samoa, and Sao Tome
Principe, Senegal, Seychelles, Sierra Leone, Sint Maarten (Netherlands
section), Solomon Islands, Somalia, South Africa, South Sudan, Sri
Lanka, St. St. Kitts and Nevis, St. Kitts St. Lucia, St. Vincent and
Grenadines, Sudan, Suriname, Tajikistan, Tanzania, Thailand,
Timor-Leste, Togo, Tonga, Trinidad & Tobago, Tunisia,
Turkmenistan, Turks & Caicos, Tuvalu, Uganda, Ukraine,
Uzbekistan, Vanuatu, Vietnam, Zambia & Zimbabwe

INDIA

In India previously also Gilead in
in 2014 signed 9 Indian companies for the blockbuster
Hepatitis drug Sofobuvir.

Indian company “excited
Life Sciences “said that they are undergoing clinical trials
regulatory approval, they further said that the drug Remdesivir
will be launched soon. Further said by the company
that “We also plan to produce Active drugs
Pharmaceutical Ingredients (API) at home help
cost effectiveness and consistent availability “

The Cipla will be permitted
to produce drugs for all 17 countries included
India and South Africa under the brand name Cipla. That’s CEO
from Cipla Limited said that “At Cipla, this is ours
continuous efforts to ensure that no patient is denied access
life-saving care. Our partnership with Gilead represents this
unwavering commitment and is a significant step towards savings
millions of people affected by this pandemic, “

The content of this article is intended to provide general information
guide to this problem. Specialist advice should be sought
about your specific situation.

.



image source

to request modification Contact us at Here or [email protected]